Podcast Episodes
Back to Search
Pharmaceutical Executive Daily: Merck's $70 Billion Investment
In today’s Pharmaceutical Executive Daily, we cover Merck’s $70 billion expansion of U.S. operations, the FDA’s latest approvals for Novo Nordisk’s R…
8 months, 3 weeks ago
Pharmaceutical Executive Daily: FDA's National Priority Voucher Program
In today’s Pharmaceutical Executive Daily, we cover the FDA’s creation of a new National Priority Voucher Program, the market reaction to President T…
8 months, 3 weeks ago
Shifting Focus in Autoimmune Diseases
Artax Biopharma’s CEO Rob Armstrong explains recent shifts in autoimmune R&D before discussing his leadership style.
8 months, 3 weeks ago
Pharmaceutical Executive Daily: EMD Serono’s Agreement with US Government
In today’s Pharmaceutical Executive Daily, we explore how antibody-drug conjugate collaborations are moving beyond oncology into autoimmune diseases,…
8 months, 4 weeks ago
Pharmaceutical Executive Daily: Rethinking Workforce Development
In today’s Pharmaceutical Executive Daily, we explore how pharma leaders are rethinking workforce development at the executive level, the industry’s …
8 months, 4 weeks ago
Pharmaceutical Executive Daily: Johnson & Johnson Separating Its Orthopedics Unit
In today’s Pharmaceutical Executive Daily, we explore Johnson & Johnson’s plan to separate its orthopaedics division into a standalone company, the g…
9 months ago
Pharmaceutical Executive Daily: Direct-To-Consumer Trends
In today’s Pharmaceutical Executive Daily, we cover Takeda’s new multi-year research collaboration with Nabla Bio, how tariff and pricing pressures a…
9 months ago
Advancing Neuroscience and Rare Disease Innovation
Acadia Pharmaceuticals’ CEO Catherine Owen Adams discusses the current climate in R&D and details her leadership style.
9 months ago
Pharmaceutical Executive Daily: Policy Whiplash
In today’s Pharmaceutical Executive Daily, we cover Ypsomed’s new North Carolina manufacturing site, how pharma leaders are maintaining strategic cla…
9 months ago
Pharmaceutical Executive Daily: Most Favored Nation Order's Evolving Landscape
In today’s Pharmaceutical Executive Daily, we cover Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics, ongoing legal and market…
9 months ago